Compare Boston Scientific Corporation (BSX) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs TeraWulf Inc — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while TeraWulf Inc trades at $19.68 (market cap $9.61B). The key difference: Boston Scientific Corporation is far larger — about 6.9× TeraWulf Inc's market cap, and TeraWulf Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | WULF | |
|---|---|---|
Market Cap | $66.37B | $9.61B |
Sector | Health | Technology |
52-Week High | $108.14 | $28.98 |
52-Week Low | $42.63 | $4.76 |
Enterprise Value | $75.94B | $12.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
WULF trades at $20.89, down 4.92% on the day, with a bearish technical signal and negative earnings trends. The company reported a net loss of $661.42 million in 2025, with revenue of $168.46 million, but secured a significant 20-year, $19 billion AI infrastructure deal with Anthropic, driving positive analyst sentiment. Key support lies at $20, with resistance at $21.
The outlook hinges on execution of the Anthropic partnership, offering substantial growth potential, but high valuation ratios and persistent losses pose risks. Analyst consensus is strongly bullish with a $35.40 price target, though operational cash flow remains negative. Investors face volatility from execution delays and competitive pressures in AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
